Recent Reports on Polysaccharide-Based Materials for Drug Delivery

Kurczewska, Joanna

doi:10.3390/polym14194189

Cited by 42 publications

(29 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, some polysaccharides are able to form a helicoidal structure and they are classified depending on their charge in neutral (e.g., dextran and pullulan (PULL) ), cationic (e.g., chitosan), and anionic (e.g., HA). [ 43 ] The structure of the most investigated oligo‐ and polysaccharides are included in Table 2 .…”

Section: Polymers Based On Sugars For Rna Delivery Systemmentioning

confidence: 99%

Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide‐Based Nanomedicines

Molinar

Tannous

Meloni

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

The efficacious delivery of therapeutic nucleic acids to cancer still remains an open issue. Through the years, several strategies are developed for the encapsulation of genetic molecules exploiting different materials, such as viral vectors, lipid nanoparticles (LNPs), and polymeric nanoparticles (NPs). Indeed, the rapid approval by regulatory authorities and the wide use of LNPs complexing the mRNA coding for the spark protein for COVID‐19 vaccination paved the way for the initiation of several clinical trials exploiting lipid nanoparticles for cancer therapy. Nevertheless, polymers still represent a valuable alternative to lipid‐based formulations, due to the low cost and the chemical flexibility that allows for the conjugation of targeting ligands. This review will analyze the status of the ongoing clinical trials for cancer therapy, including vaccination and immunotherapy approaches, exploiting polymeric materials. Among those nanosized carriers, sugar‐based backbones are an interesting category. A cyclodextrin‐based carrier (CALAA‐01) is the first polymeric material to enter a clinical trial complexed with siRNA for cancer therapy, and chitosan is one of the most characterized non‐viral vectors able to complex genetic material. Finally, the recent advances in the use of sugar‐based polymers (oligo‐ and polysaccharides) for the complexation of nucleic acids in advanced preclinical stage will be discussed.

show abstract

Section: Polymers Based On Sugars For Rna Delivery Systemmentioning

confidence: 99%

Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide‐Based Nanomedicines

Molinar

Tannous

Meloni

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…The aqueous solubility of alginate helps make stable ionic gelation in proximity with multivalent ions Ca 2+ , Mg 2+ , or Zn 2+ . Due to having gelling properties and biocompatibility, it is preferred in medicine, cosmetics, pharmaceuticals, bioengineering, and food products. , The profound driving concept of nanocomposite formation relies on the cationic or neutral carboxymethyl chitosan forming polyelectrolyte complex with alginate molecule via ionic liaison between amines and the carboxyl functional group of chitosan and alginate molecule. The dissolved drugs in oleic acid are sandwiched between two biopolymer layers.…”

Section: Introductionmentioning

confidence: 99%

Co-Delivery of Naringin and Ciprofloxacin by Oleic Acid Lipid Core Encapsulated in Carboxymethyl Chitosan/Alginate Nanoparticle Composite for Enhanced Antimicrobial Activity

Almeleebia,

Akhter,

Khalilullah

et al. 2024

ACS Omega

View full text Add to dashboard Cite

A novel combination of antibiotic, ciprofloxacin (CIP) with herbal counterpart naringin (NAR) was encapsulated by an oleic acid lipid core and carboxymethyl chitosan (CM−CS)/Alginate (AG) nanoparticle composite (CIP + NAR−CM−CS/AG−NPs) for improved antimicrobial efficacy of antibiotic. Herein, this study explored the design and preparation of a composite system that enables to deliver both CIP and NAR from the oleic acid lipid core of CM− CS/AG nanoparticles using a nonsolvent ionic gelation technique. The nanoparticles (NPs) were fabricated with improved long-acting antimicrobial activity against E. coli and S. aureus. The optimized composition was investigated for physicochemical properties particle size, particle distribution, and ζ−potential. A diverse array of analytical tools was employed to characterize the optimized formulation including DSC, XRD, Malvern Zetasizer for particle size, ζ−potential, TEM, and SEM. Further, the preparation was investigated for % drug release, flux determination, antioxidant, and antimicrobial activity. The formulation stability was tested for 90 days and also evaluated formulation stability in fetal bovine serum to inspect the modification in physicochemical characteristics. NPs size was determined at 85 nm, PDI, and ζ−potential was recorded at 0.318, and 0.7 ± 0.4 mV. The % CIP and NAR entrapment efficiency and % loading were incurred as 91 ± 1.9, and 89.5 ± 1.2; 11.5 ± 0.6, and 10.8 ± 0.5%, respectively. The drug release erupted in the beginning phase followed by sustained and prolonged release for 48 h. The analytical experiments by DSC ensured the noninteracting and safe use of excipients in combination. X−ray studies demonstrated the amorphous state of the drug in the formulation. The insignificant alteration of formulation characteristics in FBS suggested stable and robust preparation. Storage stability of the developed formulation ensured consistent and uniform stability for three months. The DPPH assays demonstrated that NAR had good antioxidant capacity and supported improving antimicrobial activity of CIP. The hemolytic test suggested the developed formulation was compatible and caused insignificant RBC destruction. The in-house built formulation CIP + NAR−CM−CS/AG−NPs significantly improved the antimicrobial activity compared to CIP alone, offering a novel choice in antimicrobial application.

show abstract

“…To overcome the biosafety issues, natural polysaccharide-based nanomaterials, such as starch, cellulose, chitosan, pectin, alginate, and dextran, have been extensively exploited as ideal carriers for biomedical and pharmaceutical applications, because of their good safety, stability, hydrophilicity, biocompatibility, biodegradability, and chemical functionality [ 6 , 7 , 8 ]. Among them, chitosan oligosaccharide lactate (COL), which is the depolymerized product of chitosan with a lower degree of polymerization (≈30) and an average molecular weight (MW ≈ 5000 Da), has a higher water solubility and lower viscosity compared to chitosan, making it a more suitable candidate for pharmaceutical and biomedical applications [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Tumor Accumulation of Low-Molecular-Weight Hyaluronic Acid/Chitosan Nanocomplexes for Photothermal Therapy

Kim

Hyun

2023

Pharmaceutics

View full text Add to dashboard Cite

Targeted phototheranostic nanosystems involving both cancer-specific near-infrared (NIR) fluorescence imaging and NIR light-induced phototherapy have shown great potential to improve cancer detection and treatment. In this study, a bifunctional nanocomplex based on low-molecular-weight hyaluronic acid (LMW-HA) and chitosan oligosaccharide lactate (COL) conjugating a zwitterionic NIR dye (ZW800-1) was rationally designed and prepared, and it was simultaneously used to enhance tumor accumulation and photothermal therapy (PTT). When HA-COL-ZW nanocomplexes were intravenously injected into mice bearing NCI-H460 tumors, HA-COL-ZW revealed increased tumor accumulation with prolonged tumor retention. Moreover, the ZW800-1 incorporated in HA-COL-ZW nanocomplexes showed excellent capability to convert NIR light into heat energy at the tumor site, acting as a PTT agent. Therefore, the targeted phototherapeutic HA-COL-ZW nanocomplex is a biocompatible and effective photothermal nanoagent, which could be a good candidate for future clinical use.

show abstract

Recent Reports on Polysaccharide-Based Materials for Drug Delivery

Cited by 42 publications

References 182 publications

Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide‐Based Nanomedicines

Current Status and Trends in Nucleic Acids for Cancer Therapy: A Focus on Polysaccharide‐Based Nanomedicines

Co-Delivery of Naringin and Ciprofloxacin by Oleic Acid Lipid Core Encapsulated in Carboxymethyl Chitosan/Alginate Nanoparticle Composite for Enhanced Antimicrobial Activity

Enhanced Tumor Accumulation of Low-Molecular-Weight Hyaluronic Acid/Chitosan Nanocomplexes for Photothermal Therapy

Contact Info

Product

Resources

About